ByJohn A
Hers Cost With vs Without Insurance: How the Numbers Change
For most of what Hers sells, insurance changes nothing, because direct-pay telehealth is priced outside the benefit entirely. Insurance changes the picture in three specific places: contraception, generic prescriptions available through a plan pharmacy, and brand-name weight medication where a formulary covers it. Everything else is a cash number either way.
Why a direct-pay subscription mostly ignores coverage
Hers, the women’s brand of Hims and Hers Health, operates on a subscription model in which the consultation and the medication are bundled into a recurring charge. That charge is not a claim. Nothing is submitted, no deductible is touched, and no out-of-pocket maximum moves. Someone with excellent coverage and someone with no coverage at all pay the identical amount on that model, which is the point of it and also its main limitation. A person whose plan already covers the treatment is paying twice: once in premiums for a benefit they are not using, and once in cash for the subscription.
That is a fair trade when the covered path is slow, gated by prior authorization, or simply not available. It is a poor trade when the plan covers the same molecule at a modest copay.
Where coverage genuinely beats a cash subscription for women
Contraception is the clearest case. Under federal preventive services rules, most non-grandfathered plans must cover FDA-approved contraceptive methods prescribed for a woman with no cost sharing, which means no copay and no deductible. A cash subscription for the same prescription is straightforwardly more expensive than free. HealthCare.gov sets out the birth control benefit and the wider preventive services for women in plain terms, and this is the first place anyone comparing a women’s telehealth plan against their insurance should look.
Generic medication is the second case. Sertraline, bupropion, tretinoin, spironolactone, and topical minoxidil are all long-established generics. A plan’s generic tier, a pharmacy discount card, or a cost-plus retail pharmacy will often land below a bundled subscription that quietly includes prescriber access most people only need a few times a year. A review of androgenetic alopecia treatment options addresses cost and adherence directly, and the financial gap between a generic topical bought at a pharmacy and the same molecule inside a monthly plan is real.
Brand-name weight medication is the third. Where a formulary covers an approved product for obesity, the covered path is frequently cheaper across a year than any cash program, though prior authorization and step therapy are common. Medicare operates under separate rules on which weight products qualify, so Part D members need to check their own plan rather than reason from commercial coverage.
Sorting out whether a formulary applies takes reading, and several providers now publish that groundwork so a member is not starting from zero. Manufacturer channels such as LillyDirect and NovoCare describe their approved-product terms, while telehealth names including Ro, Hims and Hers, and Henry Meds each frame the benefit question their own way. HealthRX, for instance, sets out how GLP-1 insurance coverage tends to work before a plan is priced, which is the kind of reference that lets someone compare the covered path against a cash program without guessing at either.
| Hers service line | Typical insured path | Typical cash path | Which usually wins |
|---|---|---|---|
| Contraception | Covered with no cost sharing on most plans | Flat monthly subscription | Insurance, clearly |
| Mental health medication | Generic tier copay, plus a covered visit | Subscription bundling visit and drug | Insurance, if a prescriber is accessible |
| Skin and hair generics | Generic tier or discount card | Monthly plan including refills | Insurance or retail cash, usually |
| Approved weight medication | Formulary coverage with prior authorization | Manufacturer self-pay channel | Insurance where the formulary allows it |
| Compounded weight medication | Not covered | Cash only | Cash, because there is no alternative |
Compounded medication has no insured version
Compounded semaglutide and tirzepatide preparations are not FDA-approved products. The agency has not reviewed the specific preparation for safety, effectiveness, or manufacturing quality, and has published its concerns about unapproved versions of these drugs sold for weight loss. Insurers do not cover them, so the with-insurance and without-insurance columns are identical here. A pharmacovigilance analysis of adverse event reports involving compounded GLP-1 products, and a poison center case series on dosing errors with compounded semaglutide, are the reasons that price gap is not a pure discount.
Since the insured column is empty for compounded treatment, the only useful comparison is between cash programs. Published plan terms are what make that comparison possible, and among physician-supervised compounding programs formblends.com is one that states medication pricing and plan length before intake rather than at checkout. Manufacturer self-pay channels for approved products publish their own terms, which gives a second reference point for the same molecule.
Pregnancy, coverage, and a subscription that has to end
A weight subscription has a built-in stopping condition that a men’s plan does not. Semaglutide labeling directs discontinuation at least two months before a planned pregnancy because of the long half-life, and discontinuation when pregnancy is recognized. Tirzepatide labeling likewise directs stopping when pregnancy is recognized, and advises women on oral contraceptives to add a barrier method or switch to a non-oral method for four weeks after starting and after each dose increase. Prenatal and maternity care is an essential health benefit on marketplace plans, so the cost picture flips from cash subscription to covered care at exactly that point. Prepaying a long cash term while planning a pregnancy is the wrong instrument.
Tax-advantaged accounts are the quiet middle ground
Where a treatment is a legitimate medical expense, paying with HSA or FSA funds reduces the effective cost without involving the insurer at all. This does not lower the sticker price and it does not apply to everything a telehealth brand sells, but it is the one lever available to someone whose plan will not cover the treatment and who is not willing to switch to a covered alternative. Confirming eligibility with the plan administrator before assuming it is the step most people skip.
Frequently asked questions
Can a Hers subscription be submitted to insurance for reimbursement?
Direct-pay telehealth is generally structured outside claims processing, and compounded preparations are not covered products under any plan. Where an itemized receipt is provided, some people submit it toward a deductible, but reimbursement is not the expected outcome and should never be assumed when comparing prices.
Is contraception really free under most plans?
Federal preventive services rules require most non-grandfathered plans to cover FDA-approved contraceptive methods prescribed for a woman with no cost sharing. Grandfathered plans and certain exempt employers are outside that rule, so the plan documents settle it. When the benefit applies, a cash subscription for the same prescription is worse value.
Does Medicare change the weight medication calculation?
Yes, and not in a straightforward direction. Part D operates under its own rules about which weight products qualify for coverage, and those rules differ from commercial formularies. A Part D member should price the covered path through their own plan before treating any cash program as the cheaper option.
Why would anyone pay cash when they have coverage?
Speed, privacy, and access to a prescriber without a referral or a waiting list. Those are real goods, and for some people they justify the premium. The mistake is paying cash without checking whether the covered path existed, which is what happens when a subscription is bought before the formulary is read.
Sources
- HealthCare.gov, Birth control benefits. https://www.healthcare.gov/coverage/birth-control-benefits/
- HealthCare.gov, Preventive care benefits for women. https://www.healthcare.gov/preventive-care-women/
- CMS, Essential Health Benefits. https://www.cms.gov/marketplace/resources/data/essential-health-benefits
- CMS, Medicare Prescription Drug Coverage. https://www.cms.gov/medicare/coverage/prescription-drug-coverage
- DailyMed, Wegovy (semaglutide) prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY
- DailyMed, Zepbound (tirzepatide) prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ZEPBOUND
- FDA, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. https://pubmed.ncbi.nlm.nih.gov/40285721/
- Administration errors of compounded semaglutide reported to a poison control center: case series. https://pubmed.ncbi.nlm.nih.gov/37392810/
- Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics. https://pubmed.ncbi.nlm.nih.gov/34741573/
